Structured evidence table for Synbiotics Gut Microbiome Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Synbiotics Gut Microbiome Randomized Trial | The increasing prevalence of these conditions is associated with demographic, socioeconomic, behavioral, and environmental changes (–). | 3 | Bautista Jhommara (2026) | The gut microbiome–cardiometabolic axis: insights into obesity, type 2 diabetes, and hypertension |
| Synbiotics Gut Microbiome Randomized Trial | Such abnormalities often develop gradually, coexist within the same individual, and confer greater risk than any diagnosis considered in isolation. | 3 | Bautista Jhommara (2026) | The gut microbiome–cardiometabolic axis: insights into obesity, type 2 diabetes, and hypertension |
| Synbiotics Gut Microbiome Randomized Trial | Cardiovascular complications may therefore represent the later expression of a prolonged trajectory that begins with metabolic susceptibility and advances through clustered risk factors and cumulative physiological impairment. | 3 | Bautista Jhommara (2026) | The gut microbiome–cardiometabolic axis: insights into obesity, type 2 diabetes, and hypertension |
| Synbiotics Gut Microbiome Randomized Trial | 1 3 Cardiometabolic diseases constitute a major cause of premature morbidity, mortality, and healthcare expenditure worldwide. | 3 | Bautista Jhommara (2026) | The gut microbiome–cardiometabolic axis: insights into obesity, type 2 diabetes, and hypertension |
| Synbiotics Gut Microbiome Randomized Trial | Evidence is accumulating that changes in the composition and function of the gut microbiome may contribute to the pathogenesis of atherosclerosis, hypertension, heart failure, thrombosis and other cardiovascular phenotypes through mechanisms involving microbial metabolites, intestinal barrier dysfunction, inflammation and metabolic dysregulation. | 4 | David DE (2026) | Targeting the Gut Microbiome in Cardiovascular Disease: Current Therapeutic Strategies and Future Perspectives. |
| Synbiotics Gut Microbiome Randomized Trial | In this context, the key question of this narrative review is: how far can modulation of the gut microbiome and its metabolic functions be a clinically meaningful approach in the prevention and treatment of cardiovascular disease, and which of the currently available microbiome-targeted approaches have sufficient mechanistic and clinical evidence to justify translation into cardiovascular practice? | 4 | David DE (2026) | Targeting the Gut Microbiome in Cardiovascular Disease: Current Therapeutic Strategies and Future Perspectives. |
| Synbiotics Gut Microbiome Randomized Trial | To answer this question, we review the evidence linking the gut microbiome to major cardiovascular phenotypes, such as atherosclerosis, hypertension, heart failure, thrombosis and atrial fibrillation, with particular focus on the mechanisms through which microbial metabolites, intestinal barrier dysfunction, inflammation and metabolic dysregulation may affect cardiovascular risk. | 4 | David DE (2026) | Targeting the Gut Microbiome in Cardiovascular Disease: Current Therapeutic Strategies and Future Perspectives. |
| Synbiotics Gut Microbiome Randomized Trial | The gut microbiota is increasingly recognized as an important modulator of cardiovascular health, demonstrating complicated interactions among diet, metabolism, immunology and host physiology. | 4 | David DE (2026) | Targeting the Gut Microbiome in Cardiovascular Disease: Current Therapeutic Strategies and Future Perspectives. |
Source documents